“Bimekizumab 3-Year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-Term Pooled Analysis from Five Phase 3 3b Trials”. 2024. SKIN The Journal of Cutaneous Medicine 8 (1): s305. https://doi.org/10.25251/skin.8.supp.305.